FlowCell was founded in 2019 to develop enabling tools for life sciences. The founder Max Narovlyansky has received his Ph.D. in microfluidics with one of the field experts, Prof. Whitesides at Harvard University. He has over 15 years of experience in drug development and diagnostics. FlowCell's vision is to provide tools for precision medicine by eliminating the artificial boundary between drug development and diagnostics.
Our tools help to increase the translational value of drug development. FlowCell's approach focuses on biomarker development that provides a functional bridge between pre-clinical research and clinical trials.
Based on 0 Reviews
Add Review